Everest Medicines gains FDA approval for EVM14 cancer vaccine, boosting mRNA oncology pipeline
Everest Medicines secures FDA approval for EVM14, its first internally developed mRNA cancer vaccine, paving the way for global clinical trials. Read More
AstraZeneca moves deeper into cell therapy with $1bn EsoBiotec acquisition
AstraZeneca’s $1 billion acquisition of EsoBiotec signals a major shift in cell therapy innovation. Find out how this deal could transform cancer treatment. Read More
Johnson & Johnson’s $55bn bet: What it means for healthcare and investors
Johnson & Johnson is investing $55 billion in U.S. manufacturing, R&D, and technology, reinforcing its leadership in pharmaceuticals. Find out more. Read More
Elevation Oncology strengthens cancer drug pipeline as cash reserves hit $93m
Elevation Oncology, Inc. has released its financial results for the fourth quarter and full-year 2024, outlining significant progress in its pipeline of targeted cancer therapies. ... Read More
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a significant milestone in the clinical development of ... Read More
PAVmed secures $2.4m to advance Veris Health’s implantable cancer monitoring technology
PAVmed Inc., a diversified commercial-stage medical technology company, has completed a $2.37 million private placement financing, reinforcing its investment in Veris Health Inc., a majority-owned ... Read More
KKR takes controlling stake in India’s cancer care giant Healthcare Global Enterprises in $400m deal
In a landmark deal set to transform India's oncology landscape, KKR, a global investment giant, has signed definitive agreements to acquire a controlling stake in ... Read More
Moleculin Biotech moves forward with pivotal Annamycin trial in AML after FDA backing
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing innovative treatments for acute myeloid leukemia, has received critical guidance from the U.S. ... Read More
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking a significant advancement in immunotherapy research. The ... Read More
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges such as the U.S. loss of exclusivity ... Read More